ImmunoCellular Therapeutics aims to become an industry-leading, independent, commercial-stage cancer immunotherapy company serving patients in major markets.
In 2014, we expect to have three product candidates in clinical development that address significant unmet needs in oncology. We believe that our proprietary cancer vaccine technology platform is broadly enabling, with the potential to generate immunotherapeutic products that can improve how cancer is treated and bring meaningful benefit to patients and their families.
We are investing strategically to build the infrastructure, operational capabilities and financial resources we need to manage a growing and maturing development portfolio. Our initial efforts are in the areas of commercialization planning and readiness, including phase III manufacturing supply and distribution, regulatory preparedness and sales and marketing. As an example, we are optimizing a proprietary manufacturing process for dendritic cell vaccines with the goal of supporting and accelerating the development and potential commercialization of our products.
Our intention is to commercialize our lead product candidate, ICT-107, ourselves in major markets, such as the US and potentially Europe, should the data from our current and any future trials support registration. We are also interested in exploring partnerships for other territories and markets, as well as potentially adding to our technological capabilities.
We believe that investing now to enable our company to thrive as an independent entity is a long-term value-creating strategy to create a foundation for further progress. As our clinical pipeline advances, these strategic investments increase our attractiveness as a collaboration partner, and position us well to evaluate strategic opportunities.
We welcome inquiries from pharmaceuticals and biotechnology companies, academic institutions and other potential collaborators. For more information, please contact firstname.lastname@example.org